Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IVF showdown: which drug combo gives more usable embryos?

NCT ID NCT07457684

Disease control Sponsor: Clinique Ovo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 846 women doing their first IVF cycle to compare two drug mixes: follitropin delta plus menotropin versus follitropin alfa plus menotropin. The goal was to see which combination leads to more usable embryos and lower costs. Results help doctors choose the most effective and affordable treatment for their patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

846 people

The number who actually took part.

Started

Dec 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women who underwent their first IVF cycle between 2018 and 2024 at the ovo clinic

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women between 18-45 years included * First ovarian stimulation cycle only * Patients who used mixed protocols combining menotropin and follitropin alfa or delta * Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight. Exclusion Criteria: * Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation * Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators * Oocytes donation or fertility preservation cycles

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ivf outcomes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian hyperstimulation syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ivf outcomes Ovarian stimulation

Contacts and locations

Locations

  • Clinique ovo

    Montreal, Quebec, H4P 2S4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.